gene synthesis Camena Bioscience Closes $10M Series A Financing Round The UK-based synthetic biology startup said it will use the funding to scale its operations and to further develop its gSynth enzymatic DNA synthesis platform. Ansa Biotechnologies Accelerating Enzymatic DNA Synthesis Technology as a Commercial Service Premium The University of California, Berkeley spinout hopes to stand out in the synthetic DNA race using its polymerase-nucleotide conjugation approach. Ansa Biotechnologies Closes $68M Series A Financing The University of California, Berkeley spinout plans to use the funding to accelerate development of its enzymatic DNA synthesis technology. Molecular Assemblies Extends Series A Financing Round by $11.8M The enzymatic DNA synthesis company added money from new and existing investors to a 2019 $12.2 million Series A round led by iSelect Fund. Piper Sandler Initiates Coverage of Twist Bioscience, Codexis With Overweight Ratings The investment bank said it believes Twist's high growth is "sustainable" and that synthetic biology is the most exciting market in the life sciences sector. Mar 18, 2021 DNA Script Preparing Launch of Benchtop Enzymatic Synthesizer for 'DNA on Demand' Premium Feb 5, 2021 Twist Bioscience Reveals MRD Testing Applications, Regeneron Genotyping Project Premium Feb 4, 2021 Twist Bioscience Fiscal Q1 Revenues Grow 64 Percent; JP Morgan Downgrades to Underweight Jan 4, 2021 Evercore ISI Downgrades Twist Bioscience to In-Line Rating Dec 2, 2020 Twist Bioscience Proposes $250M Public Offering Nov 23, 2020 Twist Bioscience Plots Continued Growth With NGS Product Push Into Ag-Bio, Cancer Dx Premium Nov 23, 2020 Twist Bioscience Fiscal Q4 Revenues More Than Double Oct 20, 2020 SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating Aug 6, 2020 Twist Bioscience Q3 Revenues Grow 56 Percent Jul 29, 2020 France's DNA Script Extends Series B Financing Round to $89M Jun 4, 2020 Twist Bioscience Prices $100M Stock Offering May 21, 2020 Genomic, Synthetic Bio Platforms Power COVID-19 Antibody Discovery at Vanderbilt Lab Premium May 7, 2020 Twist Bioscience Q2 Revenues Increase 42 Percent Mar 2, 2020 Evonetix Closes £23M Series B Financing Feb 19, 2020 Twist Bioscience Announces $100M Public Stock Offering Feb 7, 2020 With Agilent Litigation Gone, Twist Bioscience Sees Long-Term Growth in Biopharma, DNA Data Storage Premium Feb 6, 2020 Twist Bioscience Settles With Agilent, Reports 49 Percent Rise in Fiscal Q1 Revenues Feb 6, 2020 Twist Bioscience Shares Soar on Speculation of Lawsuit Settlement With Agilent Jan 13, 2020 Evonetix, Imec Collaborate on Silicon Chip Manufacturing for DNA Synthesis Dec 12, 2019 Twist Bioscience Teases Products for Liquid Biopsy Market, Biopharma Collaborations Premium Load More Breaking News SARS-CoV-2 Variants of Concerns Evolved to Modify Host Immune Response, Multiomics Study Shows People in the News at GA4GH, Mercy BioAnalytics, Deepcell, One Biosciences New Products Posted to GenomeWeb: Clinical Microbiomics, Integra Biosciences, DNAstack, Bruker Angolan Namib Desert Population Analysis Uncovers New Ancestry Group With Deep Divergence Cedars-Sinai Sets Up $25M Single Cell Precision Medicine Center The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.